KAZIA RECEIVES 1.02 MILLION R&D CASH REBATE Sydney, 14 December...

KAZIA RECEIVES 1.02 MILLION R&D CASH REBATE Sydney, 14 December 2020, Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to confirm receipt of $1,018,448.10 from the Australian Taxation Office under the R&D Tax Incentive Program for the financial year ending 30 June 2020. Kazia CEO, Dr James Garner said “the R&D tax rebate is an important, non-dilutive source of funding for the Company. The amount is consistent with the expectations laid out in our financial reports, and the funds will be invested in progressing our clinical programs. This is an important year for Kazia, with multiple data read-outs anticipated over the coming months.”